CTSO Cytosorbents Corp
- Stocks
- Healthcare
- NASDAQ: CTSO
Price (delayed)
$0.741
Market cap
$46.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.17
Enterprise value
$61.34M
Relative Growth:
Rel. Growth:
69
Relative Strength:
Rel. Strength:
18
Relative Valuation:
Rel. Valuation:
26
Relative Profitability:
Rel. Profitability:
37
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the
Highlights
CTSO's EPS has soared by 68% YoY and by 39% from the previous quarter
CTSO's net income has surged by 63% year-on-year and by 39% since the previous quarter
The equity has declined by 31% year-on-year and by 20% since the previous quarter
The quick ratio is down by 10% YoY and by 7% QoQ
Key stats
What are the main financial stats of CTSO
Market
Valuations
Earnings
Shares outstanding
62.76M
Market cap
$46.51M
Enterprise value
$61.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
4
Price to sales (P/S)
1.35
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.79
Revenue
$34.26M
Gross profit
$25.07M
Operating income
-$15.94M
Net income
-$9.75M
EBIT
-$9.01M
EBITDA
-$7.31M
Free cash flow
-$10.04M
Per share
Balance sheet
Liquidity
EPS
-$0.17
EPS diluted
-$0.17
Free cash flow per share
-$0.16
Book value per share
$0.19
Revenue per share
$0.55
TBVPS
$0.77
Total assets
$47.99M
Total liabilities
$36.4M
Debt
$26.56M
Equity
$11.59M
Working capital
$13.15M
Debt to equity
2.29
Current ratio
2.34
Quick ratio
1.98
Net debt/EBITDA
-2.03
Margins
Efficiency
Dividend
EBITDA margin
-21.3%
Gross margin
73.2%
Net margin
-28.5%
Operating margin
-46.5%
Return on assets
-20.1%
Return on equity
-77.6%
Return on invested capital
-16.7%
Return on capital employed
-23.6%
Return on sales
-26.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTSO stock price
How has the Cytosorbents stock price performed over time
Intraday
-0.54%
1 week
-5.24%
1 month
-21.17%
1 year
-19.39%
YTD
-18.57%
QTD
-20.67%
Financial performance
How have Cytosorbents's revenue and profit performed over time
Revenue
$34.26M
Gross profit
$25.07M
Operating income
-$15.94M
Net income
-$9.75M
Gross margin
73.2%
Net margin
-28.5%
The net margin has surged by 67% year-on-year and by 40% since the previous quarter
CTSO's net income has surged by 63% year-on-year and by 39% since the previous quarter
Cytosorbents's operating margin has increased by 46% YoY and by 2.1% QoQ
CTSO's operating income is up by 38% year-on-year
Price vs fundamentals
How does CTSO's price correlate with its fundamentals
Growth
What is Cytosorbents's growth rate over time
Valuation
What is Cytosorbents stock price valuation
P/E
N/A
P/B
4
P/S
1.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.79
CTSO's EPS has soared by 68% YoY and by 39% from the previous quarter
The equity has declined by 31% year-on-year and by 20% since the previous quarter
CTSO's P/B is 27% lower than its last 4 quarters average of 5.5 but 3.3% higher than its 5-year quarterly average of 3.9
The stock's price to sales (P/S) is 62% less than its 5-year quarterly average of 3.6 and 35% less than its last 4 quarters average of 2.1
Cytosorbents's revenue has increased by 14% YoY and by 2.3% QoQ
Efficiency
How efficient is Cytosorbents business performance
The ROIC has soared by 72% YoY and by 42% from the previous quarter
CTSO's ROS has soared by 70% YoY and by 44% from the previous quarter
The ROA has soared by 61% YoY and by 37% QoQ
The ROE has grown by 42% YoY and by 33% from the previous quarter
Dividends
What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTSO.
Financial health
How did Cytosorbents financials performed over time
The company's total assets is 32% higher than its total liabilities
CTSO's current ratio is up by 10% year-on-year but it is down by 10% since the previous quarter
The quick ratio is down by 10% YoY and by 7% QoQ
The debt is 129% greater than the equity
The debt to equity is up by 46% year-on-year and by 26% since the previous quarter
The equity has declined by 31% year-on-year and by 20% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.